Latest stories on MBRX
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
StockTitan56 · neutralproduct/pr
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech price target lowered to $3 from $22 at H.C. Wainwright
The Fly22 · bearishanalyst
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire50 · neutralgeneral
Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53
Seeking Alpha34 · bearishearnings
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
GlobeNewswire67 · bullishearnings
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Announces Pricing of $9.3 Million Public Offering
Business Insider24 · bearishgeneral
Moleculin Announces Pricing of $9.3 Million Public Offering
StockTitan28 · bearishgeneral
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
TipRanks67 · bullishproduct/pr
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
StockTitan73 · bullishproduct/pr
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
Stocktwits News34 · bearishearnings
Moleculin Biotech Updates Investors With New Presentation
TipRanks55 · neutralgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
TipRanks63 · neutralproduct/pr
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
TipRanks63 · neutralproduct/pr
Moleculin Biotech Releases Updated Investor Information Presentation
TipRanks50 · neutralgeneral